1. Medicine

Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study

  1. Marco Bergamini
  2. Alberto Dalla Volta  Is a corresponding author
  3. Carlotta Palumbo
  4. Stefania Zamboni
  5. Luca Triggiani
  6. Manuel Zamparini
  7. Marta Laganà
  8. Luca Rinaudo
  9. Nunzia Di Meo
  10. Irene Caramella
  11. Roberto Bresciani
  12. Francesca Valcamonico
  13. Paolo Borghetti
  14. Andrea Guerini
  15. Davide Farina
  16. Alessandro Antonelli
  17. Claudio Simeone
  18. Gherardo Mazziotti  Is a corresponding author
  19. Alfredo Berruti
  1. Medical Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy
  2. Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore Della Carità Hospital, Italy
  3. Urology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy
  4. Radiation Oncology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy
  5. Tecnologie Avanzate S.r.l, Italy
  6. Radiology Unit, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy
  7. Division of Biotechnology, Department of Molecular and Translational Medicine (DMTM), University of Brescia, Italy
  8. Urology Unit, AOUI Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Italy
  9. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele-Milan, Italy
  10. Endocrinology, Diabetology and Medical Andrology Unit, Metabolic Bone Diseases and Osteoporosis Section, IRCCS Humanitas Research Hospital,, Italy
https://doi.org/10.7554/eLife.92655
Share this article
Cite this article
  1. Marco Bergamini
  2. Alberto Dalla Volta
  3. Carlotta Palumbo
  4. Stefania Zamboni
  5. Luca Triggiani
  6. Manuel Zamparini
  7. Marta Laganà
  8. Luca Rinaudo
  9. Nunzia Di Meo
  10. Irene Caramella
  11. Roberto Bresciani
  12. Francesca Valcamonico
  13. Paolo Borghetti
  14. Andrea Guerini
  15. Davide Farina
  16. Alessandro Antonelli
  17. Claudio Simeone
  18. Gherardo Mazziotti
  19. Alfredo Berruti
(2024)
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study
eLife 13:e92655.
https://doi.org/10.7554/eLife.92655
  2. Download BibTeX
  3. Download .RIS
2 figures, 2 tables and 3 additional files

Figures

Figure 1 with 1 supplement
Download asset Open asset
Changes in mean follicle-stimulating hormone (FSH) serum levels from baseline to 6 and 12 months of degarelix treatment.
Figure 1—source data 1

Data are from BLADE study database.

https://cdn.elifesciences.org/articles/92655/elife-92655-fig1-data1-v1.xls
Figure 1—figure supplement 1
Download asset Open asset
Consort diagram.
Figure 2
Download asset Open asset
Relationship between follicle-stimulating hormone (FSH) serum levels and fat body mass (FBM) (a), arm FBM (b), trunk FBM (c), and appendicular lean mass index (ALMI)/FBM ratio (d) after 12 months degarelix treatment.

R = Spearman correlation coefficient; p = p-value.

Tables

Table 1
Baseline relationships between FSH serum levels and BMD, bone turnover markers, and body composition parameters.
FSH
Correlation coefficientp
TOT BMD0.2400.218
BMD LEFT HIP0.2290.240
BMD L2–L40.1480.453
CTX−0.1150.560
BONE ALP0.0010.997
TOT fat (g)0.2740.158
Arm fat (g)0.3630.058
Leg fat (g)0.3300.087
Head fat (g)0.2280.244
Trunk fat (g)0.2490.202
TOT lean (g)0.2160.270
Arm lean (g)0.1660.400
Leg lean (g)0.1970.315
Head lean (g)0.2500.199
Trunk lean (g)0.1900.333
ALMI (appendicular lean/Ht2)0.2690.167
ALMI/FBM−0.1840.349
Android/gynoid ratio−0.0240.902

  1. Data are Spearman R.

  2. FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP: alkaline phosphatase; ALMI: appendicular lean mass index; Ht2: height squared; FBM: fat body mass.

Table 2
Relationships between FSH serum levels and BMD, bone turnover markers, and body composition parameters after 12 months degarelix treatment.
FSH at 6 monthsFSH at 12 months
Correlation coefficientpCorrelation coefficientp
TOT BMD−0.0390.843−0.1070.595
BMD L2–L40.1020.604−0.0400.844
BMD LEFT HIP0.0300.881−0.0440.829
CTX0.0510.7960.0550.785
BONE ALP0.1740.3760.2270.256
TOT fat (g)0.4900.0080.5180.006
Arm fat (g)0.5320.0040.5410.004
Leg fat (g)0.4540.0150.3280.089
Head fat (g)0.1870.3410.0930.644
Trunk fat (g)0.4830.0090.4520.018
TOT lean (g)0.0290.885−0.0360.859
Arm lean (g)0.0410.8370.0280.889
Leg lean (g)−0.1760.371−0.2850.149
Head lean (g)0.0860.663−0.0060.977
Trunk lean (g)0.1610.4140.0210.916
ALMI (appendicular lean/Ht2)−0.2290.241−0.2650.181
ALMI/FBM−0.5810.001*−0.6040.001*
Android/gynoid ratio0.1420.4720.2310.246

  1. Data are Spearman R.

  2. Bold values are those attaining statistical significance.

  3. *

    Still significant after Bonferroni correction.

  4. FSH: follicle-stimulating hormone; TOT: total; BMD: bone mineral density; CTX: C-terminal telopeptide of type I collagen; ALP: alkaline phosphatase; ALMI: appendicular lean mass index; Ht2: height squared; FBM: fat body mass.

Additional files

Supplementary file 1

Clinical and demographical data of enrolled patients at baseline.

https://cdn.elifesciences.org/articles/92655/elife-92655-supp1-v1.docx
MDAR checklist
https://cdn.elifesciences.org/articles/92655/elife-92655-mdarchecklist1-v1.pdf
Reporting standard 1

STROBE statement for prospective study.

https://cdn.elifesciences.org/articles/92655/elife-92655-repstand1-v1.pdf

Download links